The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | Final analysis of the ALPINE trial: zanubrutinib vs ibrutinib in R/R CLL
In this video, Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares the results from a final analysis of the Phase III ALPINE trial (NCT03734016), which compared zanubrutinib versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Patients treated with zanubrutinib demonstrated a superior progression-free survival (PFS) and overall response rate (ORR) compared to those treated with ibrutinib. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
